News

Catch up on coverage from the second day of Winter Clinical Miami 2026.

Harrison Nguyen, MD, MBA, MPH, FAAD, shares early career billing, coding, and mentorship tips for dermatologists at Winter Clinical Miami 2026.

A Winter Clinical Miami poster highlights intralesional cemiplimab for early CSCC, showing rapid responses and positive safety versus surgery.

At Winter Clinical Miami 2026, Linda Stein Gold, MD, FAAD, shared acne and rosacea tips and previewed psoriasis oral advances like icotrokinra.

At Winter Clinical Miami 2026, April Armstrong, MD, MPH, spotlights new pediatric topicals and JAK safety insights, plus targeted options for head-and-neck atopic dermatitis.

A poster presented at Winter Clinical Miami 2026 shows tildrakizumab is often preferred for older patients with plaque psoriasis and medically complex comorbidities.

After TMB-001 did not meet its primary end point in the ASCEND trial, LEO Pharma moved to out-license the vehicle formulation, which unexpectedly provided a response in 40% of patients.

Catch up on coverage from the first day of Winter Clinical Miami 2026.

The final case described a young woman with clinically mild hidradenitis suppurativa (HS) but significant emotional and social distress, prompting some of the most passionate discussion across the 3 roundtables.

Mark Lebwohl, MD, shares his Winter Clinical Miami 2026 highlights, including oral psoriasis peptides, atopic dermatitis advances, GLP-1 combos, and more.

Winter Clinical Miami 2026 speakers share buy-and-bill and real estate tactics for dermatologists to boost revenue and protect cash flow.

Gary Goldenberg, MD shares branding, pricing, and tech tips to grow a profitable aesthetic dermatology practice at Winter Clinical Miami 2026.

Over 70% of evaluable patients achieved near-clear or clear skin after nearly 3 years of treatment with nemolizumab.

At Winter Clinical Miami 2026, Mona Shahriari, MD, revealed a comprehensive roadmap to launch and scale dermatology clinical trials.

As Winter Clinical kicks off in Aventura, Florida, scroll through and find some faces familiar to Dermatology Times who are presenting at the meeting.

Winter Clinical Miami 2026 kicks off today with the latest dermatology updates—let us know if you're attending and stay tuned for live coverage, pearls, and interviews.

In a Derm Dispatch discussion, Renata Block, DMSc, MMS, PA-C, and Lauren Madigan, MD, review practical strategies for diagnosing and managing cutaneous mastocytosis across age groups.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Shanna Miranti, MPAS, PA-C, discuss how “taking off the clinician mask” can strengthen trust and improve shared decision-making in the exam room.

Review our content from the month of February that recognizes patients and clinicians with skin of color.

Dermatology Times is looking back on the top stories in dermatology from the month of February.

This case involved a young patient with mild to moderate hidradenitis suppurativa (HS) of the axillae, characterized by intermittent, limited lesions without tunneling or scarring. Although seemingly routine, it prompted deeper reflection.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Dermatology Times is recapping our exclusive expert interviews from the month of February.

Dermatology Times recently concluded its second annual Horizons in Advanced Practice meeting in Tampa, Florida, featuring nurse practitioners and physician assistants from across the country.

Learn more about the in-depth topics covered in the February 2026 print issue of Dermatology Times.

The first case involved a middle-aged patient with severe, long-standing hidradenitis suppurativa (HS) marked by years of active disease with extensive sinus tracts, dense scarring, chronic drainage, frequent flares, constant pain, limited mobility, and a daily life centered around symptom management.

The FDA has assigned a Prescription Drug User Fee Act target action date of December 12, 2026.

Barzolvolimab is a humanized monoclonal antibody that inhibits the KIT receptor, aiming to reduce mast cell survival and activity in chronic spontaneous urticaria.

Revance and Teoxane’s RHA Dynamic Volume earns FDA approval for midface lift, delivering natural movement and lasting cheek contour in supporting clinical trials.

More than 57% of patients with ACD reported moderate to severe quality-of-life impairment, with symptoms and embarrassment among the most affected areas.